Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Adage Capital Management, L.P. and related parties report beneficial ownership of Tango Therapeutics, Inc. common stock. Adage Capital Management, Robert Atchinson, and Phillip Gross collectively report beneficial ownership of 5,600,000 shares of common stock, representing 3.44% of the class. All 5,600,000 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power. The percentage is based on 162,814,649 shares outstanding, consisting of 18,166,667 shares offered under a June 10, 2026 prospectus and 144,647,982 shares outstanding as of May 6, 2026. The filing indicates ownership of 5 percent or less of Tango’s common stock.
Tango Therapeutics, Inc. expanded its at-the-market offering program for its common stock through Leerink Partners LLC as sales agent. The company previously registered an aggregate offering price of up to $100,000,000 under a prior prospectus supplement, of which approximately $64,389,566 of shares have been sold and approximately $35,610,434 remain unsold.
On August 11, 2026, Tango filed a new prospectus supplement covering shares of common stock with an aggregate offering price of up to $400,000,000, which includes the approximately $35,610,434 of unsold shares from the prior prospectus supplement. The prior prospectus supplement has been terminated, and any future sales, if any, will be made under the new prospectus supplement and the existing automatic shelf registration statement. Goodwin Procter LLP issued a legal opinion on the newly registered shares.
Tango Therapeutics, Inc. is establishing a new at-the-market equity program to offer up to $400,000,000 of common stock through Leerink Partners as sales agent under its automatic shelf registration. Leerink may sell shares on Nasdaq Global Market, earning up to a 3.0% commission on gross sales.
The company previously had a $100,000,000 ATM under the same sales agreement and has already sold about $64.4 million, or 5,148,151 shares, which offering is now terminated. As of June 30, 2026, 168,380,091 shares were outstanding and net tangible book value was $1.025 billion, or $6.08 per share.
Illustratively, selling $400,000,000 of stock at $27.07 per share would increase net tangible book value to $1.416 billion, or $7.73 per share, implying dilution of $19.34 per share to new investors. Net proceeds are expected to fund working capital, operating expenses, and research and development, including manufacturing and clinical trial costs.
Tango Therapeutics, Inc. reported second-quarter 2026 results and provided clinical and corporate updates. Initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival in MTAP-deleted, RAS-mutant pancreatic cancer, with a generally well-tolerated safety profile. The company is working with regulators and collaborator Revolution Medicines on a registrational plan and intends to present detailed data at the 2026 ESMO Congress.
As of June 30, 2026, Tango held $1.0 billion in cash, cash equivalents and marketable securities. For the quarter, research and development expenses were $37.2 million and general and administrative expenses were $22.6 million, leading to a net loss of $55.3 million, or $0.37 per share. The company strengthened its leadership with the appointment of Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board, and outlined multiple clinical milestones expected in the second half of 2026.
Tango Therapeutics reported a larger net loss as it shifts from collaboration funding to equity capital while advancing its oncology pipeline. For the quarter ended June 30, 2026, net loss was $55.3 million versus $38.9 million a year earlier, with no collaboration revenue following the 2025 truncation of its Gilead research agreement.
Research and development expense rose to $37.2 million, driven by vopimetostat and TNG456 trials, while general and administrative expense nearly doubled to $22.6 million, largely from higher stock-based compensation. A June 2026 equity offering and at-the-market sales lifted cash, cash equivalents and marketable securities to about $1.0 billion, which the company expects will fund operations for at least 12 months.
Clinically, vopimetostat combinations showed encouraging early data in MTAP-deleted, RAS-mutant cancers, including high objective response and disease control rates in pancreatic and lung cohorts, and the company plans a Phase 3 trial in frontline pancreatic cancer. Tango is deprioritizing TNG260, TNG961 and has stopped new enrollment in TNG908 to focus resources on its PRMT5 franchise.
Tango Therapeutics amended an earlier disclosure to add the terms of a Separation Agreement with former Executive Chair Dr. Barbara Weber, whose employment and board roles ended effective August 3, 2026. The agreement was executed on August 6, 2026.
Dr. Weber is entitled to base-salary severance through December 31, 2026, paid in installments, and reimbursement of monthly COBRA premiums through the same date, conditional on not revoking the agreement. Equity terms include full acceleration of outstanding options and RSUs (subject to Compensation Committee approval) and extension of the post-termination exercise period for vested and accelerated options to the earlier of August 3, 2027 or each option’s original expiration. She will also receive a pro‑rata 2026 annual incentive, if earned based on company and individual performance, paid with other employees’ bonuses no later than March 15, 2027.
Tango Therapeutics, Inc. reports that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026, in accordance with her Amended and Restated Employment Agreement dated January 8, 2026, and that she is deemed to have resigned from all officer and board positions.
The company states that her resignation was not due to any disagreement regarding operations, practices or policies. Subject to Dr. Weber executing and not revoking a Separation Agreement, she is offered base-salary severance and COBRA reimbursement through December 31, 2026, acceleration of equity awards equal to 12 additional months of vesting, an extended stock option exercise period to the earlier of August 3, 2027 or the options’ original expirations, and a pro‑rated 2026 annual incentive payable no later than March 15, 2027. The company plans to file the Separation Agreement once it is fully effective and includes cautionary language regarding forward‑looking statements.
Tango Therapeutics, Inc. reported that Crystal Adam, President, R&D, exercised stock options to acquire 27,000 shares of common stock at $5.20 per share and, on the same date, sold 27,000 shares in two tranches of 5,267 and 21,733 shares at weighted average prices of $26.7895 and $27.3509 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025, and following the option exercise she held 287,040 stock options to purchase common shares.
TNG Therapeutics Inc. insider Adam Crystal filed a notice to sell 81,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate value of $2,201,580.00, on August 3, 2026 following an exercise of stock options. The filing also lists prior Rule 10b5-1 sales totaling 54,000 shares between June and July 2026.
Tango Therapeutics, Inc. President, R&D Crystal Adam reported an exercise-and-sell transaction in company common stock. She exercised stock options for 27,000 shares at $5.20 per share, then sold a total of 27,000 shares in open-market trades at weighted-average prices around $29–$30.
The filing shows two sale blocks: 7,371 shares at a weighted-average price of $30.2464 and 19,629 shares at $29.3424. After these transactions, Adam directly holds 115,743 shares of common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were scheduled in advance.